Phase 1 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older at the time you sign the consent form
- You must be fairly active and able to carry out daily activities with little or no limitations (this is measured by a standard scale doctors use called ECOG, scored 0-1)
- Your liver, kidneys, bone marrow, and other organs must be working well enough to safely participate (confirm with trial site for specific lab requirements)
- You must have a solid tumour that has been confirmed by biopsy or tissue sample and imaging scans, and the tumour cannot be removed by surgery, or has spread, come back, or is in an advanced stage
- In a later stage of the trial, participants must have one of these specific cancer types: non-small cell lung cancer, hormone-receptor-positive breast cancer, head and neck cancer, esophageal squamous cell cancer, or triple-negative breast cancer
- You must be able to understand and follow the study requirements, and must sign a consent form agreeing to participate
Who may not be able to join:
- No exclusion criteria were listed in the information provided (confirm all eligibility details with the trial site directly)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Director, Exelixis
Phone: 1-888-EXELIXIS (888-393-5494)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010; Dose-Escalation Stage: Safety of XB010; Dose-Escalation Stage: Duration of exposure of XB010 [Tolerability]; Dose-Escalation Stage: Dose intensity of XB010 [Tolerability]; Cohort-Expansion Stage: Preliminary antitumor activity of XB010
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.